Profile of secukinumab in the treatment of psoriasis: current perspectives
Michael Roman, Vandana K Madkan, Melvin W Chiu Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Abstract: Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-12-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | https://www.dovepress.com/profile-of-secukinumab-in-the-treatment-of-psoriasis-current-perspecti-peer-reviewed-article-TCRM |